E
li Lilly has opened the Lilly Gateway Labs San Diego, a 82,514‑sq‑ft biotech hub on the One Alexandria Square Megacampus in Torrey Pines. The facility, run with Alexandria Real Estate Equities, blends Alexandria’s state‑of‑the‑art real‑estate platform with Lilly’s scientific expertise, giving early‑stage San Diego biotech firms modular labs, customized scientific support, and access to capital and mentorship. The launch strengthens Alexandria’s position in the life‑science market and may boost its competitive edge and growth prospects.
Alexandria’s core thesis remains the sustained demand for specialized life‑science real‑estate and its track record of attracting top tenants in key innovation hubs. The Gateway Labs opening, while enhancing Alexandria’s market standing, does not alter the short‑term catalyst, which still hinges on a potential uptick in leasing velocity amid uncertain capital markets. The primary near‑term risk is tenant decision‑making delays and prolonged vacancies, which weigh on occupancy and net operating income. A recent 16‑year lease for a research hub at Campus Point—Alexandria’s largest ever—reinforces its ability to secure long‑term commitments from high‑quality tenants, providing visibility and resilience amid rising vacancy rates and market volatility. Nonetheless, investors should note that impairments and higher cap rates on asset sales remain concerns.
Financially, Alexandria is projected to generate $3.2 billion in revenue and $288.1 million in earnings by 2028, based on a modest 0.7% annual revenue decline and a $309.6 million earnings increase from the current $21.5 million loss. These forecasts imply a fair value of $97.50, representing a 16% upside to the current price.
Community fair‑value estimates (September 2025) range from $71 to $136, reflecting divergent outlooks. With tenant delays and vacancies still affecting earnings, the valuation depends on which market challenge investors prioritize. Eight alternative fair‑value estimates suggest the stock could be worth up to 15% less than its current price.
Investors can craft their own Alexandria narrative in under three minutes, using a free research report that summarizes fundamentals in a single visual. The report highlights four key rewards and one warning sign that could influence investment decisions.
Other fast‑moving opportunities include AI‑driven healthcare stocks focused on early diagnostics and drug discovery, all under $10 billion market cap, offering early‑entry potential. Emerging AI companies are also developing technologies for early disease detection, such as cancer and Alzheimer’s. Additionally, 19 U.S. stocks are projected to yield over 6% dividends next year, and only 31 companies worldwide explore or produce the rare earth metal dysprosium needed for the latest GPUs.
This article is general in nature and based on historical data and analyst forecasts. It is not financial advice and does not constitute a recommendation to buy or sell any stock. Simply Wall St has no position in any stocks mentioned.
